Evidence map›Paper›PMID 34295559›Full record

ArticleJournal of gastrointestinal oncology2021

Co-amplification of genes in chromosome 8q24: a robust prognostic marker in hepatocellular carcinoma.

Yongjian Zheng, Yuan Cheng, Cheng Zhang, Shunjun Fu, Guolin He, Lei Cai, Ling Qiu, Kunhua Huang, Qunhui Chen, Wenzhuan Xie and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yongjian ZhengSecond Department of Hepatobiliary Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Yuan ChengSecond Department of Hepatobiliary Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Cheng ZhangSecond Department of Hepatobiliary Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Shunjun FuSecond Department of Hepatobiliary Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Guolin HeSecond Department of Hepatobiliary Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Lei CaiSecond Department of Hepatobiliary Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Ling QiuSecond Department of Surgery, Dongfeng People's Hospital, Guangzhou, China.
Kunhua HuangSecond Department of Hepatobiliary Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Qunhui ChenSecond Department of Hepatobiliary Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Wenzhuan XieThe Research and Development Center of Precision Medicine, 3D Medicines Inc., Shanghai, China.
Tingting ChenThe Research and Development Center of Precision Medicine, 3D Medicines Inc., Shanghai, China.
Mengli HuangThe Research and Development Center of Precision Medicine, 3D Medicines Inc., Shanghai, China.
Yuezong BaiThe Research and Development Center of Precision Medicine, 3D Medicines Inc., Shanghai, China.
Mingxin PanSecond Department of Hepatobiliary Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Zhujiang Hospital · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a leading cause of tumor-associated death worldwide, owing to its high 5-year postoperative recurrence rate and inter-individual heterogeneity. Thus, a prognostic model is urgently needed for patients with HCC. Several researches have reported that copy number amplification of the 8q24 chromosomal region is associated with low survival in many cancers. In the present work, we set out to construct a multi-gene model for prognostic prediction in HCC.

methodsRNA sequencing and copy number variant data of tumor tissue samples of HCC from The Cancer Genome Atlas (n=328) were used to identify differentially expressed messenger RNAs of genes located on the chromosomal 8q24 region by the Wilcox test. Univariate Cox and Lasso-Cox regression analyses were carried out for the screening and construction of a prognostic multi-gene signature in The Cancer Genome Atlas cohort (n=119). The multi-gene signature was validated in a cohort from the International Cancer Genome Consortium (n=240). A nomogram for prognostic prediction was built, and the underpinning molecular mechanisms were studied by Gene Set Enrichment Analysis.

resultsWe successfully established a 7-gene prognostic signature model to predict the prognosis of patients with HCC. Using the model, we divided individuals into high-risk and low-risk sets, which showed a significant difference in overall survival in the training dataset (HR =0.17, 95% CI: 0.1-0.28; P<0.001) and in the testing dataset (HR = 0.42, 95% CI: 0.23-0.74; P=0.002). Multivariate Cox regression analysis showed the signature to be an independent prognostic factor of HCC survival. A nomogram including the prognostic signature was constructed and showed a better predictive performance in short-term (1 and 3 years) than in long-term (5 years) survival. Furthermore, Gene Set Enrichment Analysis identified several pathways of significance, which may aid in explaining the underlying molecular mechanism.

conclusionsOur 7-gene signature is a reliable prognostic marker for HCC, which may provide meaningful information for therapeutic customization and treatment-related decision making.

Indexed as

8q24amplificationHepatocellular carcinoma (HCC)International Cancer Genome Consortium (ICGC)prognostic modelThe Cancer Genome Atlas (TCGA)

Identifiers

PMID34295559
PMCPMC8261314
OpenAlexW3134628267

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.